Company Overview

Company name: PhytoTech Therapeutics
Description: Developer of cannabinoid-based prescription drugs created with advanced oral delivery formulations in Israel. The company’s drugs mainly uses proprietary drug delivery technologies, which are delivered only the therapeutic components of Cannabis through the oral and buccal routes, enabling patients to avail drugs based on medical cannabis.
Year founded: 2014
Parent company:
Industry: Healthcare | Group: Pharmaceuticals and Biotechnology | Code:
Country: Israel
Region: Middle East

Financial Highlights

Start up capital raised (USD Million):
Business status: Generating Revenue
Ownership: Privately Held (no backing)
Revenue (USD Million):
Gross profit (USD Million):
Net income (USD Million)
Enterprise value:
Earnings before interest, tax, depreciation and amortization (EBITDA):
Fiscal period:
Financing Status: The company reached a definitive agreement to be acquired by Harvest One Cannabis (TSX: HVT) for $8 million on June 25, 2018. The acquisition will enable the acquirer to expand its position in the pharmaceutical market in Israel. Upon completion, $1 million in cash and $7 million in Harvest One common shares issued at the then 10-day volume weighted average closing price, will be paid to MMJ.
Number of active investors:
Profile last updated: 19-Sep-2018
Last known valuation: 8.00
Last known valuation date: 25-Jun-2018